EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

From Remedy to Therapy: Confronting the Bioavailability Bottleneck in Ganoderma lucidum Translational Research

Yujie Qu iD, Xinyu Zhao iD, Hongxin Liu, Rutong Ren, Wenran Qu, Shili Wang, Guohua Ma iD

Pharmaceuticals · 2026-07-27 · 19 (8) · 1171

DOI: 10.3390/ph19081171 ↗

At a glance

Übersichtsarbeit in Pharmaceuticals, published online on 2026-07-27. Written by Yujie Qu and 6 co-authors. Institution: Medical School, Shandong Xiehe University, Jinan 250109, China. 90 references. The full text is freely available (open access, CC BY 4.0). Funded by: China National Center for Biotechnology Development, Key Laboratory of Guangdong Province, National Key Research & Development Program of China.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background/Objectives: For over two millennia, Ganoderma lucidum has served as a traditional remedy, yet its translation into evidence-based therapy remains stymied by a persistent obstacle. Potent in vitro activities consistently fail to translate in vivo, a shortfall rooted in the poor systemic bioavailability of its signature triterpenoids and polysaccharides. We contend that the defining hurdle is no longer compound discovery but whether emerging formulation technologies genuinely overcome these barriers or merely sidestep them in ways that obscure the underlying physiology.

Methods

We construct a structure–activity–formulation (SAF) prioritization framework. We critically survey a broad spectrum of delivery platforms—including lipid-based, polymeric, micellar, tellurium nanorod, and G. lucidum-derived vesicular systems—against their demonstrated capacity to improve oral exposure. Clinical assessments and regulatory considerations are integrated to anchor the analysis in translational reality.

Results

Bioavailability has been systematically treated as a post hoc variable, even though the very structural features conferring bioactivity impose the steepest systemic barriers. To date, no G. lucidum nanoformulation has advanced to human trials, and the regulatory terrain for these complex natural-product nanomedicines remains uncharted. We distill three experimentally tractable propositions—testing lipid-mediated absorption, triple-helix conformational dependency, and co-delivery synergy—that offer discrete entry points for rigorous investigation.

Conclusions

We argue that the field must pivot decisively from descriptive cataloging to hypothesis-driven, comparative investigation, anchored by reference-material standardization and proactive regulatory dialogue. Confronting the bioavailability bottleneck as a primary design parameter—rather than an ancillary nuisance—represents the most credible route from historical remedy to evidence-based therapeutic.

Subjects

Author keywords

Ganoderma lucidumbioavailabilitydrug deliverynanotechnologypolysaccharidestranslational medicinetriterpenoids

Authors and institutions

  • Medical School, Shandong Xiehe University, Jinan 250109, China.
  • Guangdong Provincial Key Laboratory of Applied Botany, South China Botanical Garden, The Chinese Academy of Sciences, Guangzhou 510650, China.
  • College of Life Science, University of the Chinese Academy of Sciences, Beijing 100049, China.

ORCID profiles: Yujie Qu, Xinyu Zhao, Guohua Ma

Funding

  • China National Center for Biotechnology Development
  • Key Laboratory of Guangdong Province
  • National Key Research & Development Program of China
  • Guangdong Key Areas Biosafety Project

Cite

APA

Qu, Y., Zhao, X., Liu, H., Ren, R., Qu, W., Wang, S., & Ma, G. (2026). From Remedy to Therapy: Confronting the Bioavailability Bottleneck in Ganoderma lucidum Translational Research. Pharmaceuticals, 19(8), 1171. https://doi.org/10.3390/ph19081171

Vancouver

Qu Y, Zhao X, Liu H, Ren R, Qu W, Wang S, et al. From Remedy to Therapy: Confronting the Bioavailability Bottleneck in Ganoderma lucidum Translational Research. Pharmaceuticals. 2026;19(8):1171. doi:10.3390/ph19081171

BibTeX
@article{Qu2026,
  author = {Qu, Yujie and Zhao, Xinyu and Liu, Hongxin and Ren, Rutong and Qu, Wenran and Wang, Shili and Ma, Guohua},
  title = {From Remedy to Therapy: Confronting the Bioavailability Bottleneck in Ganoderma lucidum Translational Research},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1171},
  doi = {10.3390/ph19081171}
}
Start for free →